AbbVie (NYSE:ABBV) Trading Down 3.9% – Here’s Why

AbbVie Inc. (NYSE:ABBV) shares were down 3.9% during mid-day trading on Thursday . The company traded as low as $223.12 and last traded at $224.22. Approximately 9,265,758 shares were traded during mid-day trading, an increase of 14% from the average daily volume of 8,144,709 shares. The stock had previously closed at $233.42.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Berenberg upgrades AbbVie to a Buy, giving the stock some analyst support that could limit downside if results meet guidance. Article Title
• Positive Sentiment: Pipeline progress: AbbVie advanced a Phase 2 icalcaprant trial in depression — a clinical development readout to monitor that could add upside if data are positive. Article Title
• Positive Sentiment: AbbVie launched a first‑in‑human ABBV‑901 ovarian cancer trial — early‑stage upside tied to successful dose/safety readouts and long‑term pipeline optionality. Article Title
• Positive Sentiment: Real‑world study wrap‑ups for Rinvoq (Korea) and upadacitinib (Japan) may produce real‑world safety/usage data that support commercial momentum in IBD and atopic dermatitis. Article Title
• Positive Sentiment: Dividend support: a Seeking Alpha piece highlights AbbVie’s dividend reliability — a factor that attracts income investors and can buoy the stock during short‑term volatility. Article Title
• Neutral Sentiment: AbbVie set its Q4 2025 EPS guidance at 3.320–3.360 and FY2025 at 10.610–10.650 — slightly below consensus, so upcoming results/footnotes will determine how the market reacts. (Company guidance release)
• Neutral Sentiment: Company will report FY/Q4 2025 results and host an earnings call on Feb. 4 — this is the next major catalyst for clarity on sales, margins and one‑time items. Article Title
• Neutral Sentiment: Sector/partner news: an Ironwood pricing move involving LINZESS (AbbVie is a commercial partner) is changing dynamics in that franchise — relevant but indirect for AbbVie’s overall earnings. Article Title
• Negative Sentiment: M&A reversal: after reports (WSJ/Reuters) that AbbVie was in talks to buy Revolution Medicines lifted shares, AbbVie denied it is in talks — the denial removed the takeover premium and pressured the stock. Article Title
• Negative Sentiment: Accounting hit: AbbVie disclosed that IPR&D and related expenses will negatively impact Q4 EPS — investors will watch the earnings release for the size and one‑time nature of these charges. Article Title

Analyst Ratings Changes

A number of brokerages have recently weighed in on ABBV. Wells Fargo & Company upped their price target on shares of AbbVie from $240.00 to $260.00 and gave the stock an “overweight” rating in a research note on Friday, September 12th. Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. Raymond James Financial set a $256.00 price target on AbbVie in a research report on Monday, November 3rd. Berenberg Bank raised AbbVie from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $170.00 to $270.00 in a research note on Wednesday, September 17th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, October 8th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and a consensus target price of $246.89.

AbbVie Stock Down 3.9%

The company has a market capitalization of $396.28 billion, a price-to-earnings ratio of 169.86, a price-to-earnings-growth ratio of 0.94 and a beta of 0.36. The business has a 50-day moving average price of $226.63 and a 200-day moving average price of $214.80.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. During the same quarter in the previous year, the company earned $3.00 EPS. The business’s revenue for the quarter was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, sell-side analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a $1.73 dividend. The ex-dividend date is Friday, January 16th. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. AbbVie’s dividend payout ratio is currently 524.24%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Marshall & Sullivan Inc. WA purchased a new stake in shares of AbbVie in the second quarter worth approximately $25,000. Evolution Wealth Management Inc. acquired a new position in AbbVie in the 2nd quarter valued at approximately $26,000. Chelsea Counsel Co. acquired a new position in AbbVie in the 3rd quarter valued at approximately $26,000. Spurstone Advisory Services LLC purchased a new stake in AbbVie in the 2nd quarter worth approximately $28,000. Finally, Texas Capital Bancshares Inc TX acquired a new stake in shares of AbbVie during the 3rd quarter valued at $31,000. 70.23% of the stock is owned by institutional investors and hedge funds.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.